Operating Segments (Tables)

12 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Segment Revenue, Operating Income from Continuing Operations and Depreciation and Amortization

The tables below present segment revenue, operating income from continuing operations and depreciation and amortization, for the years ended September 30, as follows (in thousands):

	2013			2012			2011
Revenue:
Medical Device	$	41,153		$	37,883		$	39,606
In Vitro Diagnostics		14,979			14,045			13,150
Total revenue	$	56,132		$	51,928		$	52,756
Operating income (loss):
Medical Device	$	21,164		$	18,431		$	19,997
In Vitro Diagnostics		4,222			4,542			4,314
Total segment operating income		25,386			22,973			24,311
Corporate		(6,566	)		(6,631	)		(8,788	)
Total operating income from continuing operations	$	18,820		$	16,342		$	15,523
Depreciation and amortization:
Medical Device	$	1,255		$	1,414		$	1,604
In Vitro Diagnostics		864			774			799
Corporate		767			741			756
Total depreciation and amortization	$	2,886		$	2,929		$	3,159

Revenue from Major Customers

Revenue from customers that equaled or exceeded 10% of total revenue was as follows for the years ended September 30:

	2013			2012			2011
Medtronic		19	%		19	%		18	%
Johnson & Johnson		**			**			16	%

** -less than 10%

Geographic Revenue

Geographic revenue was as follows for the years ended September 30:

	2013			2012			2011
Domestic		79	%		79	%		73	%
Foreign		21	%		21	%		27	%